• Ana Carolina Tramontina, Francine Tramontina, Larissa D Bobermin, Caroline Zanotto, Daniela F Souza, Marina C Leite, Patrícia Nardin, Carmem Gottfried, and Carlos-Alberto Gonçalves.
• Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600- Anexo, 90035-003, Porto Alegre, Brazil.
• Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008 Aug 1;32(6):1580-3.

AbstractS100B is a calcium-binding protein, produced and secreted by astrocytes, which has a putative paracrine neurotrophic activity. Clinical studies have suggested that peripheral elevation of this protein is positively correlated with a therapeutic antidepressant response, particularly to selective serotonin reuptake inhibitors (SSRIs); however, the mechanism underlying this response remains unclear. Here, we measured S100B secretion directly in hippocampal astrocyte cultures and hippocampal slices exposed to fluoxetine and observed a significant increment of S100B release in the presence of this SSRI, apparently dependent on protein kinase A (PKA). Moreover, we found that serotonin (possibly via the 5HT1A receptor) reduces S100B secretion and antagonizes the effect of fluoxetine on S100B secretion. These data reinforce the effect of fluoxetine, independently of serotonin and serotonin receptors, suggesting a putative role for S100B in depressive disorders and suggesting that other molecular targets may be relevant for antidepressant activity.

28 keywords...

hide…